Kevin Gibson
Pulmonary Disease · Pittsburgh, PANPI 1285607283
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 2 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Boehringer Ingelheim accounts for 83.9% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for pulmonary disease clinicians in PA, where the typical reported total is $988.
Across 2 payments — averaging $68.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$114
- Genentech USA, Inc.$22
Across 93 payments — averaging $14,157 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$583K
- Kadmon Corporation LLC$276K
- E.r. Squibb & Sons, L.L.C.$223K
- Novartis$148K
- Bristol Myers Squibb$49K
- Biogen$22K
- plus $15K from 4 others
What the payments were for
- Food & beverage$136100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 1 | $114 |
| Genentech USA, Inc. | 1 | $22 |
How this compares
$136 in reported general payments places this provider in the 20th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 122 | $97,194 |
| Breo ElliptaFluticasone/Vilanterol | 106 | $49,524 |
| Arnuity ElliptaFluticasone Furoate | 49 | $13,256 |
| Spiriva RespimatTiotropium Bromide | 13 | $8,673 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $8,347 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 44 | $7,103 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $6,993 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 131 | $3,781 |
| MethotrexateMethotrexate Sodium | 149 | $3,419 |
| Wixela InhubFluticasone Propion/Salmeterol | 22 | $2,637 |
| Azelastine Hcl | 121 | $2,251 |
| Mycophenolate Mofetil | 20 | $2,214 |
| Ventolin HfaAlbuterol Sulfate | 22 | $1,203 |
| Fluticasone Propionate | 70 | $1,006 |
| Azathioprine | 34 | $857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $114 | $15,66628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Pittsburgh
- Tariq CheemaPittsburgh$549K
- Stephen BashedaPittsburgh$455K
- Khalid MalikPittsburgh$144K
- Patrick StrolloPittsburgh$124K
- Frank SciurbaPittsburgh$119K
- Sohini GhoshPittsburgh$112K
- Brian CarlinPittsburgh$102K
- Lewis KlinePittsburgh$99K
- Sally WenzelPittsburgh$70K
- Michael ApostolisPittsburgh$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.